Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology
This article was originally published in Start Up
Executive Summary
The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.
You may also be interested in...
Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.
Imagen's Ophthalmology In-Licensing Strategy Attracts $40M Series A
With a plan to take advantage of scientific advances suggesting that compounds for cancer and other diseases may have facility in the eye, Imagen will seek ideal candidates for dry AMD.
Imagen Biotech Inc.
With time to exit an increasingly important metric for VCs, jump-starting new companies via in-licensing remains an important and oft-used strategy. Such derisking is one of the defining principles behind Imagen Biotech, a new ophthalmic play still operating in stealth mode. Imagen plans to pursue new leads for sight-threatening diseases, including dry age-related macular degeneration.